Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Russian Multicenter Clinical Trial
Background. Recent advances in the treatment of relapsed/refractory acute lymphoblastic leukemia (R/R ALL) are attributed to the implementation of immunotherapy methods which include blinatumomab, the bispecific engager of a patient’s endogenous T-cells (Blincyto™, Amgen®) (BC). Aim. To assess BC e...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Practical Medicine Publishing House
2019-03-01
|
| Series: | Клиническая онкогематология |
| Subjects: | |
| Online Access: |
http://bloodjournal.ru/wp-content/uploads/2019/03/4-1.pdf
|
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849309133060177920 |
|---|---|
| author | SN Bondarenko EN Parovichnikova AA Maschan OYu Baranova TV Shelekhova VA Doronin VYa Mel’nichenko KD Kaplanov OS Uspenskaya AN Sokolov NV Myakova IS Moiseev IV Markova EI Darskaya AG Smirnova TA Bykova BI Ayubova IA Samorodova EV Babenko IM Barkhatov TL Gindina AD Kulagin BV Afanas’ev |
| author_facet | SN Bondarenko EN Parovichnikova AA Maschan OYu Baranova TV Shelekhova VA Doronin VYa Mel’nichenko KD Kaplanov OS Uspenskaya AN Sokolov NV Myakova IS Moiseev IV Markova EI Darskaya AG Smirnova TA Bykova BI Ayubova IA Samorodova EV Babenko IM Barkhatov TL Gindina AD Kulagin BV Afanas’ev |
| author_sort | SN Bondarenko |
| collection | DOAJ |
| description | Background. Recent advances in the treatment of relapsed/refractory acute lymphoblastic leukemia (R/R ALL) are attributed to the implementation of immunotherapy methods which include blinatumomab, the bispecific engager of a patient’s endogenous T-cells (Blincyto™, Amgen®) (BC).
Aim. To assess BC efficacy and toxicity in the treatment of R/R ALL patients with persistence of minimal tumor clone before and after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Materials & Methods. The trial included 66 B-ALL patients with CD19+ aged 18 to 72 years, 23 (35 %) of them with measurable minimal residual disease (MRD+) and 43 (65 %) with R/R ALL. In 18 (27 %) patients BC was administered after prior allo-HSCT.
Results. In the overall group 2-year overall survival (OS) and disease-free survival (DFS) in patients with response to BC treatment were 53 % and 38 % respectively. In the R/R ALL group complete remission (CR) was achieved in 29 (67 %) patients including 24 (83 %) patients with negative MRD. CR rate was higher in standard cytogenetic risk group (73 %) in comparison with high-risk group (59 %). In patients with more or less than 50 % blast cells in bone marrow CR rate was 85 % and 61 %, respectively. When BC was administered after prior allo-HSCT and without it CR rate was 80 % and 60 %, respectively. In R/R ALL patients with response to BC 2-year OS and DFS were 40 % and 26 %, respectively, in the MRD+ group of ALL patients they were 66 % and 51 %, respectively. Relapse rate was lower in the group with allo-HSCT than in the group without it, i.e. 21 % vs. 55 %. Adverse events of grade 3–4 were observed in 25 (38 %) patients. In 11 (16 %) patients BC therapy had to be discontinued, in 5 (7 %) patients it was terminated prior to the scheduled date.
Conclusion. BC efficacy is higher in the MRD+ group and in R/R ALL patients with smaller tumor mass. BC treatment after allo-HSCT yields remissions in most patients and can be combined with immune-adoptive therapy. |
| format | Article |
| id | doaj-art-0d0f02c0aa0f40d183029f5d92fe5db2 |
| institution | Kabale University |
| issn | 1997-6933 2500-2139 |
| language | Russian |
| publishDate | 2019-03-01 |
| publisher | Practical Medicine Publishing House |
| record_format | Article |
| series | Клиническая онкогематология |
| spelling | doaj-art-0d0f02c0aa0f40d183029f5d92fe5db22025-08-20T03:54:15ZrusPractical Medicine Publishing HouseКлиническая онкогематология1997-69332500-21392019-03-0112214515310.21320/2500-2139-2019-12-2-145-15319976933Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Russian Multicenter Clinical TrialSN Bondarenko0EN Parovichnikova1AA Maschan2OYu Baranova3TV Shelekhova4VA Doronin5VYa Mel’nichenko6KD Kaplanov7OS Uspenskaya8AN Sokolov9NV Myakova10IS Moiseev11IV Markova12EI Darskaya13AG Smirnova14TA Bykova15BI Ayubova16IA Samorodova17EV Babenko18IM Barkhatov19TL Gindina20AD Kulagin21BV Afanas’ev22 RM Gorbacheva Scientific Research Institute of Pediatric Oncology, Hematology and Transplantation; IP Pavlov First Saint Petersburg State Medical University, 6/8 L’va Tolstogo str., Saint Petersburg, Russian Federation, 197022 National Medical Hematology Research Center, 4а Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167 Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, 1 Samory Mashela str., Moscow, Russian Federation, 117997 NN Blokhin National Medical Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478 VI Razumovskii Saratov State Medical University, 112 Bol’shaya Kazach’ya str., Saratov, Russian Federation, 410012 Municipal Clinical Hospital No. 40, 7 Kasatkina str., Moscow, Russian Federation, 129301 NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203 Volgograd Regional Clinical Oncologic Dispensary, 78 Zemlyachki str., Volgograd, Russian Federation, 400138 Leningrad Regional Clinical Hospital, 45–49 Lunacharskogo pr-t, Saint Petersburg, Russian Federation, 194291 National Medical Hematology Research Center, 4а Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167 Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, 1 Samory Mashela str., Moscow, Russian Federation, 117997 RM Gorbacheva Scientific Research Institute of Pediatric Oncology, Hematology and Transplantation; IP Pavlov First Saint Petersburg State Medical University, 6/8 L’va Tolstogo str., Saint Petersburg, Russian Federation, 197022 RM Gorbacheva Scientific Research Institute of Pediatric Oncology, Hematology and Transplantation; IP Pavlov First Saint Petersburg State Medical University, 6/8 L’va Tolstogo str., Saint Petersburg, Russian Federation, 197022 RM Gorbacheva Scientific Research Institute of Pediatric Oncology, Hematology and Transplantation; IP Pavlov First Saint Petersburg State Medical University, 6/8 L’va Tolstogo str., Saint Petersburg, Russian Federation, 197022 RM Gorbacheva Scientific Research Institute of Pediatric Oncology, Hematology and Transplantation; IP Pavlov First Saint Petersburg State Medical University, 6/8 L’va Tolstogo str., Saint Petersburg, Russian Federation, 197022 RM Gorbacheva Scientific Research Institute of Pediatric Oncology, Hematology and Transplantation; IP Pavlov First Saint Petersburg State Medical University, 6/8 L’va Tolstogo str., Saint Petersburg, Russian Federation, 197022 RM Gorbacheva Scientific Research Institute of Pediatric Oncology, Hematology and Transplantation; IP Pavlov First Saint Petersburg State Medical University, 6/8 L’va Tolstogo str., Saint Petersburg, Russian Federation, 197022 RM Gorbacheva Scientific Research Institute of Pediatric Oncology, Hematology and Transplantation; IP Pavlov First Saint Petersburg State Medical University, 6/8 L’va Tolstogo str., Saint Petersburg, Russian Federation, 197022 RM Gorbacheva Scientific Research Institute of Pediatric Oncology, Hematology and Transplantation; IP Pavlov First Saint Petersburg State Medical University, 6/8 L’va Tolstogo str., Saint Petersburg, Russian Federation, 197022 RM Gorbacheva Scientific Research Institute of Pediatric Oncology, Hematology and Transplantation; IP Pavlov First Saint Petersburg State Medical University, 6/8 L’va Tolstogo str., Saint Petersburg, Russian Federation, 197022 RM Gorbacheva Scientific Research Institute of Pediatric Oncology, Hematology and Transplantation; IP Pavlov First Saint Petersburg State Medical University, 6/8 L’va Tolstogo str., Saint Petersburg, Russian Federation, 197022 RM Gorbacheva Scientific Research Institute of Pediatric Oncology, Hematology and Transplantation; IP Pavlov First Saint Petersburg State Medical University, 6/8 L’va Tolstogo str., Saint Petersburg, Russian Federation, 197022 RM Gorbacheva Scientific Research Institute of Pediatric Oncology, Hematology and Transplantation; IP Pavlov First Saint Petersburg State Medical University, 6/8 L’va Tolstogo str., Saint Petersburg, Russian Federation, 197022 Background. Recent advances in the treatment of relapsed/refractory acute lymphoblastic leukemia (R/R ALL) are attributed to the implementation of immunotherapy methods which include blinatumomab, the bispecific engager of a patient’s endogenous T-cells (Blincyto™, Amgen®) (BC). Aim. To assess BC efficacy and toxicity in the treatment of R/R ALL patients with persistence of minimal tumor clone before and after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Materials & Methods. The trial included 66 B-ALL patients with CD19+ aged 18 to 72 years, 23 (35 %) of them with measurable minimal residual disease (MRD+) and 43 (65 %) with R/R ALL. In 18 (27 %) patients BC was administered after prior allo-HSCT. Results. In the overall group 2-year overall survival (OS) and disease-free survival (DFS) in patients with response to BC treatment were 53 % and 38 % respectively. In the R/R ALL group complete remission (CR) was achieved in 29 (67 %) patients including 24 (83 %) patients with negative MRD. CR rate was higher in standard cytogenetic risk group (73 %) in comparison with high-risk group (59 %). In patients with more or less than 50 % blast cells in bone marrow CR rate was 85 % and 61 %, respectively. When BC was administered after prior allo-HSCT and without it CR rate was 80 % and 60 %, respectively. In R/R ALL patients with response to BC 2-year OS and DFS were 40 % and 26 %, respectively, in the MRD+ group of ALL patients they were 66 % and 51 %, respectively. Relapse rate was lower in the group with allo-HSCT than in the group without it, i.e. 21 % vs. 55 %. Adverse events of grade 3–4 were observed in 25 (38 %) patients. In 11 (16 %) patients BC therapy had to be discontinued, in 5 (7 %) patients it was terminated prior to the scheduled date. Conclusion. BC efficacy is higher in the MRD+ group and in R/R ALL patients with smaller tumor mass. BC treatment after allo-HSCT yields remissions in most patients and can be combined with immune-adoptive therapy. http://bloodjournal.ru/wp-content/uploads/2019/03/4-1.pdf acute lymphoblastic leukemiatargeted therapyblinatumomab |
| spellingShingle | SN Bondarenko EN Parovichnikova AA Maschan OYu Baranova TV Shelekhova VA Doronin VYa Mel’nichenko KD Kaplanov OS Uspenskaya AN Sokolov NV Myakova IS Moiseev IV Markova EI Darskaya AG Smirnova TA Bykova BI Ayubova IA Samorodova EV Babenko IM Barkhatov TL Gindina AD Kulagin BV Afanas’ev Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Russian Multicenter Clinical Trial Клиническая онкогематология acute lymphoblastic leukemia targeted therapy blinatumomab |
| title | Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Russian Multicenter Clinical Trial |
| title_full | Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Russian Multicenter Clinical Trial |
| title_fullStr | Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Russian Multicenter Clinical Trial |
| title_full_unstemmed | Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Russian Multicenter Clinical Trial |
| title_short | Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Russian Multicenter Clinical Trial |
| title_sort | blinatumomab in the treatment of acute lymphoblastic leukemia russian multicenter clinical trial |
| topic | acute lymphoblastic leukemia targeted therapy blinatumomab |
| url |
http://bloodjournal.ru/wp-content/uploads/2019/03/4-1.pdf
|
| work_keys_str_mv | AT snbondarenko blinatumomabinthetreatmentofacutelymphoblasticleukemiarussianmulticenterclinicaltrial AT enparovichnikova blinatumomabinthetreatmentofacutelymphoblasticleukemiarussianmulticenterclinicaltrial AT aamaschan blinatumomabinthetreatmentofacutelymphoblasticleukemiarussianmulticenterclinicaltrial AT oyubaranova blinatumomabinthetreatmentofacutelymphoblasticleukemiarussianmulticenterclinicaltrial AT tvshelekhova blinatumomabinthetreatmentofacutelymphoblasticleukemiarussianmulticenterclinicaltrial AT vadoronin blinatumomabinthetreatmentofacutelymphoblasticleukemiarussianmulticenterclinicaltrial AT vyamelnichenko blinatumomabinthetreatmentofacutelymphoblasticleukemiarussianmulticenterclinicaltrial AT kdkaplanov blinatumomabinthetreatmentofacutelymphoblasticleukemiarussianmulticenterclinicaltrial AT osuspenskaya blinatumomabinthetreatmentofacutelymphoblasticleukemiarussianmulticenterclinicaltrial AT ansokolov blinatumomabinthetreatmentofacutelymphoblasticleukemiarussianmulticenterclinicaltrial AT nvmyakova blinatumomabinthetreatmentofacutelymphoblasticleukemiarussianmulticenterclinicaltrial AT ismoiseev blinatumomabinthetreatmentofacutelymphoblasticleukemiarussianmulticenterclinicaltrial AT ivmarkova blinatumomabinthetreatmentofacutelymphoblasticleukemiarussianmulticenterclinicaltrial AT eidarskaya blinatumomabinthetreatmentofacutelymphoblasticleukemiarussianmulticenterclinicaltrial AT agsmirnova blinatumomabinthetreatmentofacutelymphoblasticleukemiarussianmulticenterclinicaltrial AT tabykova blinatumomabinthetreatmentofacutelymphoblasticleukemiarussianmulticenterclinicaltrial AT biayubova blinatumomabinthetreatmentofacutelymphoblasticleukemiarussianmulticenterclinicaltrial AT iasamorodova blinatumomabinthetreatmentofacutelymphoblasticleukemiarussianmulticenterclinicaltrial AT evbabenko blinatumomabinthetreatmentofacutelymphoblasticleukemiarussianmulticenterclinicaltrial AT imbarkhatov blinatumomabinthetreatmentofacutelymphoblasticleukemiarussianmulticenterclinicaltrial AT tlgindina blinatumomabinthetreatmentofacutelymphoblasticleukemiarussianmulticenterclinicaltrial AT adkulagin blinatumomabinthetreatmentofacutelymphoblasticleukemiarussianmulticenterclinicaltrial AT bvafanasev blinatumomabinthetreatmentofacutelymphoblasticleukemiarussianmulticenterclinicaltrial |